Efficacy and safety of once‐weekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the SURMOUNT ‐2 trial

Figures

• 

  FIGURE 1. Patient disposition. Flow diagram of Japanese participants from the SURMOUNT‐2 trial included in the analysis (one study site was excluded due to a regulatory noncompliance issue). ITT, intention‐to‐treat; N, number of participants in the analysis population.

• 

  FIGURE 2. Effect of tirzepatide on body weight and waist circumference. Japanese participants were treated with once‐weekly tirzepatide (10 or 15 mg) or placebo. Data are for the modified intention‐to‐treat population (efficacy analysis set). For each parameter, only participants with a non‐missing baseline value and at least one non‐missing postbaseline value were included in the analysis. (A) Percent change from baseline in body weight from baseline to week 72. Postbaseline data are from MMRM analyses. (B) LSM (±SE) change from baseline in body weight at week 72. Postbaseline data are from MMRM analyses. (C) Proportion of participants achieving body weight reduction thresholds. Results are from logistic regression with missing values imputed by an MMRM. (D) LSM (SE) change in waist circumference at week 72. Postbaseline data are from MMRM analyses. LSM, least‐squares mean; MMRM, mixed model for repeated measures; SE, standard error. *p < 0.05 vs. placebo, **p < 0.01 vs. placebo, ***p < 0.001 vs. placebo.

• 

  FIGURE 3. Effect of tirzepatide on glycemic parameters. Japanese participants were treated with once‐weekly tirzepatide (10 or 15 mg) or placebo. Data are for the modified intention‐to‐treat population (efficacy analysis set). For each parameter, only participants with a non‐missing baseline value and at least one non‐missing postbaseline value were included in the analysis. (A) Time course of HbA1c values from baseline to week 72. An MMRM was used for postbaseline measures. Data are presented as LSM (SE). (B) Proportion of participants reaching HbA1c targets. Analyses were based on logistic regression with missing values imputed by an MMRM. (C) Time course of FSG values from baseline to week 72. A MMRM model was used for postbaseline measures. Data are presented as LSM (SE). FSG, fasting serum glucose; HbA1c, glycated haemoglobin; LSM, least‐squares mean; MMRM, mixed model for repeated measures; SE, standard error. **p < 0.01 vs. placebo, ***p < 0.001 vs. placebo.